📣 VC round data is live. Check it out!
- Public Comps
- Genematrix
Genematrix Valuation Multiples
Discover revenue and EBITDA valuation multiples for Genematrix and similar public comparables like Finemedix, AnteoTech, Spirit Scientific Co, IMD International Medical and more.
Genematrix Overview
About Genematrix
Genematrix Inc is a biotech company engaged in the development of the platform and molecular diagnostics products. Its products include NeoPlexTM STI-7 Detection kit, OmniPlex-HPV, PapilloTyper, HepB Typer-Adefovir, and HepB Typer-Precore among others.
Founded
2000
HQ

Employees
N/A
Website
Financials (FY)
EV
$20M
Valuation Multiples
Start free trialGenematrix Financials
Genematrix reported last fiscal year revenue of $7M and negative EBITDA of ($802K).
In the same fiscal year, Genematrix generated $4M in gross profit, ($802K) in EBITDA losses, and had net loss of ($1M).
Genematrix P&L
In the most recent fiscal year, Genematrix reported revenue of $7M and EBITDA of ($802K).
Genematrix is unprofitable as of last fiscal year, with gross margin of 59%, EBITDA margin of (11%), and net margin of (17%).
Financial data powered by Morningstar, Inc.
Genematrix Stock Performance
Genematrix has current market cap of $28M, and enterprise value of $20M.
Genematrix's stock price is $1.39.
Genematrix has an EPS (earnings per share) of $-0.06.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $20M | $28M | -0.4% | — | — | — | $-0.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGenematrix Valuation Multiples
Genematrix trades at 2.7x EV/Revenue multiple, and (24.8x) EV/EBITDA.
Genematrix Financial Valuation Multiples
As of May 10, 2026, Genematrix has market cap of $28M and EV of $20M.
Genematrix has a P/E ratio of (22.1x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Genematrix Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Genematrix Margins & Growth Rates
In the most recent fiscal year, Genematrix reported gross margin of 59%, EBITDA margin of (11%), and net margin of (17%).
Genematrix Margins
Genematrix Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Genematrix Operational KPIs
Data powered by FactSet, Inc. and Morningstar, Inc.
Genematrix Competitors
Genematrix competitors include Finemedix, AnteoTech, Spirit Scientific Co, IMD International Medical, CS Diagnostics, Vivos, Harvard Bioscience, Polyrizon, Medclair and European Medical Solutions.
Most Genematrix public comparables operate across Diagnostics & Genomics, Medical Devices, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 4.0x | — | (25.3x) | — | |||
| 40.1x | 43.3x | (7.6x) | (11.5x) | |||
| 2.2x | — | 10.6x | — | |||
| 0.4x | — | 5.6x | — | |||
| — | — | 356.9x | — | |||
| 422.9x | — | (9.1x) | — | |||
| 0.8x | 0.8x | 8.2x | 8.0x | |||
| — | — | (5.8x) | — | |||
This data is available for Pro users. Sign up to see all Genematrix competitors and their valuation data. Start Free Trial | ||||||
Genematrix Investment Activity
Genematrix has invested in 1 company to date.
Latest investment by Genematrix was on December 20th 2018. Genematrix invested in Barinthus Biotherapeutics in their $8M Series A round (EV/Revenue multiple of ).
Latest Investments by Genematrix
| Description | Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines. |
| HQ Country | |
| HQ City | Oxford |
| Deal Date | 20 Dec 2018 |
| Round | Series A |
| Raised | $8M |
| Investors | GeneMatrix; Korea Investment Partners |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Genematrix investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Genematrix
| When was Genematrix founded? | Genematrix was founded in 2000. |
| Where is Genematrix headquartered? | Genematrix is headquartered in South Korea. |
| Is Genematrix publicly listed? | Yes, Genematrix is a public company listed on Korea Exchange. |
| What is the stock symbol of Genematrix? | Genematrix trades under 109820 ticker. |
| When did Genematrix go public? | Genematrix went public in 2009. |
| Who are competitors of Genematrix? | Genematrix main competitors include Finemedix, AnteoTech, Spirit Scientific Co, IMD International Medical, CS Diagnostics, Vivos, Harvard Bioscience, Polyrizon, Medclair, European Medical Solutions. |
| What is the current market cap of Genematrix? | Genematrix's current market cap is $28M. |
| What is the current revenue of Genematrix? | Genematrix's last fiscal year revenue is $7M. |
| What is the current EV/Revenue multiple of Genematrix? | Current revenue multiple of Genematrix is 2.7x. |
| Is Genematrix profitable? | No, Genematrix is not profitable. |
| How many companies Genematrix has acquired to date? | Genematrix hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Genematrix has invested to date? | As of May 2026, Genematrix has invested in 1 company. |
| What was the last Genematrix investment? | On 20th December 2018 Genematrix invested in Barinthus Biotherapeutics, participating in a $8M Series A round, alongside Korea Investment Partners. |
| In what companies Genematrix invested in? | Genematrix invested in Barinthus Biotherapeutics. |
See public comps similar to Genematrix
Lists including Genematrix
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
